Track topics on Twitter Track topics that are important to you
Johnson & Johnson’s Janssen Biotech will use Zymeworks’ Azymetric™ and Effector Function Enhancement and Control Technology (EFECT™) platforms to research, develop, and commercialize up to six bispecific antibodies directed to unspecified Janssen therapeutic targets, through a licensing agreement that Zymeworks said today could generate for it up to $1.4 billion-plus. The collaboration is Zymeworks’ sixth with a biopharma giant, and the first since its wholly-owned lead product candidate ZW25, developed through Azymetric, entered clinical trials. “The proceeds from this collaboration will be primarily used to fund the clinical advancement of ZW25, as well as the advancement of our preclinical programs into the clinic,” Zymeworks President and CEO Ali Tehrani, Ph.D., said in a statement. ZW25 is a bispecific antibody designed to treat HER2-expressing cancers by simultaneously binding two non-overlapping epitopes—called biparatopic binding—of HER2, resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein ...NEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...